Xolair (omalizumab) Limitation of Use: Xolair is not indicated for treatment of other forms of urticaria.
|
|
- Robert Austin
- 7 years ago
- Views:
Transcription
1 Xolair (omalizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 11/18/2003 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy. FDA-Approved Indications Asthma Xolair is indicated for patients 6 years of age and older with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. Xolair has been shown to decrease the incidence of asthma exacerbations in these patients. Limitations of Use: Xolair is not indicated for the relief of acute bronchospasm or status asthmaticus. Xolair is not indicated for treatment of other allergic conditions. Chronic Idiopathic Urticaria (CIU) Xolair is indicated for the treatment of adults and adolescents (12 years of age and above) with chronic idiopathic urticaria who remain symptomatic despite H1 antihistamine treatment. Limitation of Use: Xolair is not indicated for treatment of other forms of urticaria. B. REQUIRED DOCUMENTATION The following documentation from the medical record is necessary to initiate the prior authorization review: Allergic asthma, initial therapy: o Current medications (including doses) o Member current weight o Pre-treatment serum IgE (IU/mL) levels o Skin or blood test results confirming the diagnosis of allergic asthma o Clinical notes documenting failure of environmental controls and immune therapy o FEV1 results o Clinical notes documenting treatment of comorbidities
2 Xolair 2 o Quality of Life Measures Survey (available at vey.pdf) Chronic idiopathic urticaria (CIU), initial therapy: o Clinical notes supporting a diagnosis of CIU for at least 3 months o Clinical notes supporting trial and failure of all previous antihistamines, including length of courses Allergic asthma, continuation of therapy: o Either comparative FEV1 results or Quality of Life Measures Survey o Current medications (including doses) CIU, continuation of therapy: o o Documentation supporting that the member has responded to therapy For members demonstrating a complete response: documentation must support tapering of dose and/or withholding of therapy beyond the next dosing interval to see if symptoms return C. PRESCRIBER RESTRICTION For allergic asthma, the specialty of the prescriber who recommended Xolair is an allergist, immunologist, or pulmonologist. For CIU, the specialty of the prescriber who recommended Xolair is an allergist, immunologist, or dermatologist. D. INITIAL CRITERIA FOR APPROVAL 1. Allergic Asthma Authorization of 6 months may be granted to members who are prescribed Xolair when ALL of the following criteria are met: a. Prior to initiating therapy, the severity of the member s asthma is moderate or severe persistent b. The member is 6 years of age or older c. Xolair will be administered in a controlled healthcare setting with access to emergency medications if needed d. The member s asthma is inadequately controlled with the use of an inhaled corticosteroid at the optimized dose e. The member s asthma is inadequately controlled with the use of a long acting beta agonist at the optimized dose f. The member s current weight is less than or equal to 150 kg g. The member s pre-treatment IgE level is greater than or equal to 30 IU/mL h. The prescribed Xolair dose follows FDA-approved dosing recommendations (for dose and dosing frequency) based on pre-treatment serum IgE levels and body weight (See prescribing information at i. Prior to initiating therapy, the member has positive skin or in vitro reactivity to at least one perennial aeroallergen j. The member has failed environmental controls and standard immune therapy, unless there is evidence that immune therapy will trigger a severe allergic reaction
3 Xolair 3 k. The member s pre-treatment forced expiratory volume (FEV1) is less than 80% of predicted value l. The member s comorbidities have been evaluated and treated m. The member has a rapid-acting beta 2 agonist available for rescue therapy n. The member has completed a current HMSA Asthma Quality of Life Measures Survey (available at 2. Chronic idiopathic urticaria (CIU) Authorization of 3 months may be granted to members who are prescribed Xolair when ALL of the following criteria are met: a. Prior to initiating therapy, the severity of the member s CIU is moderate or severe b. The member is 12 years of age or older c. Xolair will be administered in a controlled healthcare setting with access to emergency medications if needed d. The member has been diagnosed with CIU for 3 months or longer e. The member has been evaluated for other causes of urticaria f. The member remained symptomatic despite treatment with at least 2 distinct courses of different high-dose second generation H1 antihistamines used continuously for at least 2 weeks, unless contraindicated (See Appendix) g. The member remained symptomatic despite treatment with a first generation H1 antihistamine (eg, hydroxyzine, doxepin) or an H2 antihistamine (eg, ranitidine) in combination with a high-dose second generation H1 antihistamine used continuously for at least 2 weeks, unless contraindicated (See Appendix) E. CONTINUATION OF THERAPY 1. Allergic asthma Authorization of 6 additional months may be granted to members who were previously authorized by HMSA when ALL of the following criteria are met. After the first year, authorization of 12 additional months may be granted to members when ALL of the following criteria are met: a. The member has shown improvement (or sustained improvement) in one of the following measures since initiation of Xolair therapy: i. Improvement in forced expiratory volume (FEV1) ii. Decrease in hospitalizations or emergency room visits iii. Overall increase in quality of life measures based on the HMSA Quality of Life Measures Survey (available at _Survey.pdf) b. The member will continue to use inhaled corticosteroids 2. Chronic idiopathic urticaria (CIU) Authorization of additional 6 months may be granted to members who were previously authorized by HMSA when either criterion a) or b) below is met. After the first year, authorization of 12 additional months may be granted to members when either criterion a) or b) below is met: a. The member has demonstrated a partial response since initiation of Xolair therapy
4 Xolair 4 b. The member has demonstrated a complete response since initiation of Xolair therapy AND symptoms returned when the dose was tapered or withheld beyond the next dosing interval F. DOSAGE AND ADMINISTRATION Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. G. APPENDIX High-dose second generation H1 antihistamines are defined as twice daily dosing of standard daily dosing (listed below): Cetirizine (Zyrtec ) 10 mg Levocetirizine (Xyzal ) 5 mg Fexofenadine (Allegra ) 180 mg Loratadine (Claritin ) 10 mg Desloratadine (Clarinex ) 5 mg H. IMPORTANT REMINDER The purpose of this Medical Policy is to provide a guide to coverage. This Medical Policy is not intended to dictate to providers how to practice medicine. Nothing in this Medical Policy is intended to discourage or prohibit providing other medical advice or treatment deemed appropriate by the treating physician. Benefit determinations are subject to applicable member contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. This Medical Policy has been developed through consideration of the medical necessity criteria under Hawaii s Patients Bill of Rights and Responsibilities Act (Hawaii Revised Statutes 432E-1.4), generally accepted standards of medical practice and review of medical literature and government approval status. HMSA has determined that services not covered under this Medical Policy will not be medically necessary under Hawaii law in most cases. If a treating physician disagrees with HMSA s determination as to medical necessity in a given case, the physician may request that CVS/caremark reconsider the application of the medical necessity criteria to the case at issue in light of any supporting documentation. I. REFERENCES 1. Xolair [package insert]. South San Francisco, CA: Genentech, Inc.; July Busse, W. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med. 2001; 164 (8 part 2):S12-S FDA Talk Paper. FDA approves first biologic for allergy-related asthma. June 20, Global strategy for asthma management and prevention. Updated Available at: 5. Holgate S, et al. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin. 2001; 17(4): Kaplan A1, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, Veith J, Kamath N, et.al J Allergy Clin Immunol. Omalizumab in patients with symptomatic chronic idiopathic/ spontaneous urticaria despite standard combination therapy Jul;132(1):101-9.
5 Xolair 5 7. Khan, DA. Chronic urticaria: Standard management and patient education. UpToDate Khan, DA. Chronic urticaria: Treatment of refractory symptoms. UpToDate Maurer M1, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, Casale T. N Engl J Med. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria Mar 7;368(10): Epub 2013 Feb National Institutes of Health, National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. NAEPP Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. Bethesda, Maryland: U.S. Department of Health and Human Services; July Powell RJ, Du Toit GL, Siddique N, Leech SC, Dixon TA, Clark AT, Mirakian R, Walker SM, Huber PA, Nasser SM; British Society for Allergy and Clinical Immunology (BSACI). BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy May;37(5): Practice Parameters for Allergen Immunotherapy. IX. Safety of Immunotherapy. Summary Statement 12. Ann Allergy: 2003; 90:S (Third update is in draft as of 10/18/2010.) 13. Saini, S. Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history. UpToDate Soler M, Matz J, Townley R, et al. The anti-ige antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001; 18(2): Zuberbier T. World Allergy Organ J. A Summary of the New International EAACI/GA2LEN/EDF/WAO Guidelines in Urticaria Jan; 5 Suppl 1:S Zuberbier T1, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, Grattan CE, Kapp A, Maurer M, Merk HF, et.al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy Oct;64(10): Revised: August 2016.
9/16/2014. Anti-Immunoglobulin E (IgE) Omalizumab (Xolair ) Dosing Guidance
Disclosure Statement of Financial Interest New Therapies for Asthma Including Omalizumab and Anti-Cytokine Therapies Marsha Dangler, PharmD, BCACP Clinical Pharmacy Specialist James H. Quillen VA Medical
More informationGROWTH HORMONE THERAPY
GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below including FDA-approved
More informationClassifying Asthma Severity and Initiating Treatment in Children 0 4 Years of Age
Classifying Asthma Severity and Initiating Treatment in Children 0 4 Years of Age Components of Severity Symptoms Intermittent 2 days/week Classification of Asthma Severity (0 4 years of age) Persistent
More informationCorporate Medical Policy Allergy Immunotherapy (Desensitization)
Corporate Medical Policy Allergy Immunotherapy (Desensitization) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: allergy_immunotherapy 7/1979 11/2014 11/2015 10/2015 Description
More informationAllergy Shots and Allergy Drops for Adults and Children. A Review of the Research
Allergy Shots and Allergy Drops for Adults and Children A Review of the Research Is This Information Right for Me? This information may be helpful to you if: Your doctor* has said that you or your child
More informationSevere asthma Definition, epidemiology and risk factors. Mina Gaga Athens Chest Hospital
Severe asthma Definition, epidemiology and risk factors Mina Gaga Athens Chest Hospital Difficult asthma Defined as asthma, poorly controlled in terms of chronic symptoms, with episodic exacerbations,
More informationGrowth Hormone Therapy
Growth Hormone Therapy Policy Number: Original Effective Date: MM.04.011 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 10/28/2011 Section: Prescription Drugs Place(s) of Service:
More informationPOLICY A. INDICATIONS
Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below
More informationAn Overview of Asthma - Diagnosis and Treatment
An Overview of Asthma - Diagnosis and Treatment Asthma is a common chronic disorder of the airways that is complex and characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness,
More informationAnaphylaxis: A Life Threatening Allergic Reaction
Anaphylaxis: A Life Threatening Allergic Reaction What is Anaphylaxis? Anaphylaxis is a sudden, severe, and potentially fatal allergic reaction that can cause a wide range of symptoms, including breathing
More informationAllergy Testing Test Request and Result Interpretation. Learning Objectives
Allergy Testing Test Request and Result Interpretation Dr. Kareena Schnabl, MSc, PhD, FCACB Clinical Biochemist, Genetic Laboratory Services University of Alberta Hospital Newborn Screening & Biochemical
More information3. Asthme et immunothérapie sublinguale (SLIT)
Dr. Guillaume Buss Service d immunologie et allergie, CHUV Formation continue «asthme et allergies» Lausanne, le 8 octobre 2015 1. Historique 2. Asthme et immunothérapie sous-cutanée (SCIT) 1. Mécanismes
More informationIdentification of Allergic Disease Among Users of Antihistamines
ORIGINAL RESEARCH Identification of Allergic Disease Among Users of Antihistamines SHERYL L. SZEINBACH, PhD; P. BROCK WILLIAMS, PhD; PIETER MUNTENDAM, MD; and RICHARD D. O CONNOR, MD ABSTRACT OBJECTIVE:
More informationPATIENT INFORMATION ABOUT TREATMENTS FOR ASTHMA AND ALLERGIC RHINITIS, PRESCRIPTIONS & OVER THE COUNTER MEDICINE
PATIENT INFORMATION ABOUT TREATMENTS FOR ASTHMA AND ALLERGIC RHINITIS, PRESCRIPTIONS & OVER THE COUNTER MEDICINE The content of this booklet was developed by Allergy UK. MSD reviewed this booklet to comment
More informationCLINICAL NURSE LPN, RN, BSN,
Comprehensive asthma care often requires a team of health professionals, each with specific skills and eperience in asthma diagnosis, treatment, patient education and counseling. Benefits of Team Care
More informationSupplement Questions asked in the 1st International Basic Allergy Course
Supplement Questions asked in the 1st International Basic Allergy Course 1. CLINICAL MANIFESTATION What is the percentage of people who have both combined food and inhalant? What is the difference between
More informationPage 1 of 15 Origination Date: 09/14 Revision Date(s): 10/2015, 02/2016 Developed By: Medical Criteria Committee 10/28/2015
Moda Health Plan, Inc. Medical Necessity Criteria Subject: Actemra (tocilizumab) Page 1 of 15 Origination Date: 09/14 Revision Date(s): 10/2015, 02/2016 Developed By: Medical Criteria Committee 10/28/2015
More informationAdrenaline autoinjector (EpiPen) for acute allergic anaphylaxis
for acute allergic anaphylaxis This review of adrenaline autoinjector was first published in December 2003. This update describes the change to the PBS listing to allow prescribing immediately after hospital
More informationBackground information
Background information Asthma Asthma is a complex disease affecting the lungs that can be managed but cannot be cured. 1 Asthma can be controlled well in most people most of the time, although some people
More informationThe Right Medicines Can Help You Get Control of Asthma. BlueCare SM TennCareSelect
The Right Medicines Can Help You Get Control of Asthma BlueCare SM TennCareSelect WHEEZING. COUGHING. SHORTNESS OF BREATH. CHEST TIGHTNESS. If you or a family member has asthma, you know these symptoms
More informationCOPD and Asthma Differential Diagnosis
COPD and Asthma Differential Diagnosis Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death in America. Learning Objectives Use tools to effectively diagnose chronic obstructive
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization
More informationName of Policy: Antigen Leukocyte Cellular Antibody Test (ALCAT)
Name of Policy: Antigen Leukocyte Cellular Antibody Test (ALCAT) Policy #: 165 Latest Review Date: February 2015 Category: Laboratory Policy Grade: C Background/Definitions: As a general rule, benefits
More informationMARYLAND STATE SCHOOL HEALTH SERVICES GUIDELINES
Department of Health and Mental Hygiene Maryland State Department of Education Maryland State School Health Council MARYLAND STATE SCHOOL HEALTH SERVICES GUIDELINES Emergency Management Guidelines for
More informationHow to use FENO-guided asthma control in routine clinical practice
How to use FENO-guided asthma control in routine clinical practice Asthma is a chronic inflammatory disease of the airways. This has implications for the diagnosis, management and potential prevention
More informationLetter Date March 27, 2007 Stamp Date March 28, 2007 PDUFA Goal Date January 28, 2008
CLINICAL REVIEW Application Type NDA Submission Number 22-157 Submission Code Letter Date March 27, 2007 Stamp Date March 28, 2007 PDUFA Goal Date January 28, 2008 Reviewer Name Review Completion Date
More informationThe Annual Direct Care of Asthma
The Annual Direct Care of Asthma The annual direct health care cost of asthma in the United States is approximately $11.5 billion; indirect costs (e.g. lost productivity) add another $4.6 billion for a
More informationALLERGENIC EXTRACT. Prescription Set of Serial Dilutions (or Maintenance Vial (s)) INSTRUCTIONS FOR USE. U.S. Government License No.
ALLERGENIC EXTRACT Prescription Set of Serial Dilutions (or Maintenance Vial (s)) INSTRUCTIONS FOR USE U.S. Government License No. 308 Revised 07/04 PO Box 800 Lenoir, NC 28645 USA DESCRIPTION This set
More informationAAAAI Allergy, Asthma & Immunology Quality Clinical Data Registry in collaboration with CECity
AAAAI Allergy, Asthma & Immunology Quality Clinical Data Registry in collaboration with CECity Measure Specifications Hosting Measures Owned and Developed by: American Medical Association-convened Physician
More informationPublic Assessment Report. Pharmacy to General Sales List Reclassification. Pirinase Hayfever Relief for Adults 0.05% Nasal Spray.
Public Assessment Report Pharmacy to General Sales List Reclassification Pirinase Hayfever Relief for Adults 0.05% Nasal Spray (Fluticasone) PL 00079/0688 Glaxo Wellcome UK Limited TABLE OF CONTENTS Introduction
More informationEmergency Anaphylaxis Management: Opportunities for Improvement. Ronna Campbell, MD, PhD August 31, 2015
Emergency Anaphylaxis Management: Opportunities for Improvement Ronna Campbell, MD, PhD August 31, 2015 disclosures Anaphylaxis Roundtable discussion held at the 2014 American College of Allergy, Asthma
More informationRise of the killer peanuts
Rise of the killer peanuts Epi Then, Epi Now Taher Vohra, MD Henry Ford Hospital Department of Emergency Medicine ObjecCves To define anaphylaxis To review the epidemiology of anaphylaxis To discuss treatments
More informationmeasured before the start of treatment, and body weight (kg). See the dose determination charts. (2.1)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XOLAIR safely and effectively. See full prescribing information for XOLAIR. XOLAIR (omalizumab) for
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationUS Food and Drug Administration
US Food and Drug Administration Meeting of the Pulmonary-Allergy Drugs Advisory Committee November 18, 2009 Badrul A. Chowdhury, MD, PhD Director, Division of Pulmonary and Allergy Products, Office of
More informationAllergy Testing Clinical Coverage Policy No: 1N-1 Amended Date: October 1, 2015. Table of Contents
Table of Contents 1.0 Description of the Procedure, Product, or Service... 1 1.1 Definitions... 1 2.0 Eligible Beneficiaries... 2 2.1 Provisions... 2 2.1.1 General... 2 2.1.2 Specific... 2 2.2 Special
More informationYOU VE BEEN REFERRED TO AN ASTHMA SPECIALIST...
YOU VE BEEN REFERRED TO AN ASTHMA SPECIALIST... ...HERE S WHAT TO EXPECT You have been referred to an allergist because you have or may have asthma. The health professional who referred you wants you to
More informationOmalizumab for Asthma
clinical therapeutics Omalizumab for Asthma Robert C. Strunk, M.D., and Gordon R. Bloomberg, M.D. This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion
More informationRecombinant allergens provide new opportunities. The diagnostic tools of tomorrow are already here
Recombinant allergens provide new opportunities The diagnostic tools of tomorrow are already here Recombinant allergens provide new opportunities The diagnostic tools of tomorrow are already here Today
More informationReceived for publication March 15, 2003. Accepted for publication in revised form June 2, 2003. 32 ANNALS OF ALLERGY, ASTHMA, & IMMUNOLOGY
Design and baseline characteristics of The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma
More informationManagement of exacerbations in chronic obstructive pulmonary disease in Primary Care
Management of exacerbations in chronic obstructive pulmonary disease in Primary Care Acute exacerbations of chronic obstructive pulmonary disease (COPD) are associated with significant morbidity and mortality.
More informationSelective IgA deficiency (slgad) hello@piduk.org 0800 987 8986 www.piduk.org
Selective IgA deficiency (slgad) hello@piduk.org 0800 987 8986 www.piduk.org About this booklet This booklet provides information on selective IgA deficiency (sigad). It has been produced by the PID UK
More informationAllergies: ENT and Allergy Center of Missouri YOUR GUIDE TO TESTING AND TREATMENT. University of Missouri Health Care
Allergies: YOUR GUIDE TO TESTING AND TREATMENT ENT and Allergy Center of Missouri University of Missouri Health Care 812 N. Keene St., Columbia, MO 65201 (573) 817-3000 www.muhealth.org WHAT CAUSES ALLERGIES
More informationCLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15
Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationBefore, Frank's immune cells could
Before, Frank's immune cells could barely recognize a prostate cancer cell. Now, they are focused on it. Stimulate an immune response against advanced prostate cancer Extend median survival beyond 2 years
More informationPrimary Care Management of Food Allergy and General Public Knowledge and Beliefs
Primary Care Management of Food Allergy and General Public Knowledge and Beliefs Ruchi S. Gupta, MD, MPH Associate Professor of Pediatrics Ann and Robert H. Lurie Children s Hospital Northwestern Feinberg
More informationApplied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder
Applied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder Policy Number: Original Effective Date: MM.12.022 01/01/2016 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration
More informationA ragweed pollen as a treatment for a ragweed allergy? It s called immunotherapy.
A ragweed pollen as a treatment for a ragweed allergy? It s called immunotherapy. RAGWITEK is a prescription medicine used for sublingual (under the tongue) immunotherapy to treat ragweed pollen allergies
More information5. Treatment of Asthma in Children
Treatment of sthma in hildren 5. Treatment of sthma in hildren 5.1 Maintenance Treatment 5.1.1 rugs Inhaled Glucocorticoids. Persistent wheezing in children under the age of three can be controlled with
More informationAsthma POEMs. Patient Orientated Evidence that Matters
ASTHMA POEMs Asthma POEMs Patient Orientated Evidence that Matters Developed by the Best Practice Advocacy Centre Level 8, 10 George Street PO Box 6032 Dunedin Phone 03 4775418 Fax 03 4772622 Acknowledgement
More informationTreatment of Asthma. Talk to your doctor about the various medications available to treat asthma.
Please call 911 if you think you have a medical emergency. Treatment of Asthma The goals of asthma therapy are to prevent your child from having chronic and troublesome symptoms, to maintain your child's
More informationAsthma (With a little SCID to start) Disclosures Outline Starting with the Immune System The Innate Immune System The Adaptive Immune System
1 2 3 4 5 6 7 8 9 Asthma (With a little SCID to start) Lauren Smith, MD CHKD Pediatric Allergy/Immunology Disclosures None Will be discussing some medications that are not yet FDA approved Outline SCID
More informationOn completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children
7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists
More informationXOLAIR [omalizumab] For injection, for subcutaneous use Initial U.S. Approval: 2003 WARNING: ANAPHYLAXIS
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. XOLAIR [omalizumab] For injection,
More information5.07.04. Provigil Nuvigil. Provigil (modafinil) / Nuvigil (armodafinil) Description. Section: Prescription Drugs Effective Date: July 1, 2015
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.04 Subject: Provigil Nuvigil Page: 1 of 6 Last Review Date: June 19, 2015 Provigil Nuvigil Description
More informationThe Problem with Asthma. Ruth McArthur, Practice Nurse/Trainer
The Problem with Asthma Ruth McArthur, Practice Nurse/Trainer Getting the diagnosis right! Asthma or COPD? History taking is key Both are inflammatory conditions with different mechanisms & mediators Diagnostic
More informationManagement of an anaphylactic reaction to Omalizumab (Xolair) drug therapy
Management of an anaphylactic reaction to Omalizumab (Xolair) drug therapy Turnberg Building Respiratory Medicine 0161 206 3158 All Rights Reserved 2014. Document for issue as handout. What is an allergic
More informationMonoclonal Antibodies in Asthma Therapy. Yehia El-Gamal MD, PhD
Monoclonal Antibodies in Asthma Therapy Yehia El-Gamal MD, PhD Conflict of Interest Nothing to disclose Objectives Following this presentation, the audience should be able to: Recognize some important
More informationThe Proper Treatment Of Asthma
The Proper Treatment Of Asthma Southwest Allergy & Asthma Foundation Page 1 of 10 INTRODUCTION The purpose of this pamphlet is to supply information which will give patients suffering with asthma, an intelligent
More informationEight Guiding Principles for Effective Use of IVIG for Patients with Primary Immunodeficiency
Eight Guiding Principles for Effective Use of IVIG for Patients with Primary Immunodeficiency Primary immunodeficiency is caused by inherent defects of the immune system and results in recurrent, severe
More informationMontelukast 10mg film-coated tablets PL 17907/0474
Montelukast 10mg film-coated tablets PL 17907/0474 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 11 Steps Taken After Initial Authorisation Page
More informationADMINISTRATION OF MEDICATIONS POLICY
Policy 6.007. ADMINISTRATION OF MEDICATIONS POLICY It is the policy of Cooperative Educational Services (C.E.S.) that students who require any medications to be administered during school hours, including
More informationRichard L. Barnes, D.O., F.O.C.O.O
SAFETY OF HOME-BASED IMMUNOTHERAPY Richard L. Barnes, D.O., F.O.C.O.O Introduction Taking immunotherapy injections at home presents a greater risk from a medico legal standpoint than receiving injections
More informationGlossary of Terms. Section Glossary. of Terms
Glossary of Terms Section Glossary of Terms GLOSSARY Acute: Symptoms which can occur suddenly with a short and severe course. Adrenaclick /Generic Adrenaclick : a single use epinephrine auto-injector that
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationPHARMACEUTICAL MANAGEMENT PROCEDURES
PHARMACEUTICAL MANAGEMENT PROCEDURES THE FORMULARY The purpose of Coventry Health Care s formulary is to encourage use of the most cost-effective drugs. The formulary is necessary because the cost of prescription
More informationAnnotated from the NAEPP/NHLBI Updated Asthma Guidelines and Developed Through Expert Consensus
Asthma Pocket Guide for Primary Care Annotated from the NAEPP/NHLBI Updated Asthma Guidelines and Developed Through Expert Consensus POSITION STATEMENT Despite advances in therapy, asthma remains a disease
More informationGuidelines for anaphylaxis emergency medication (adrenaline [epinephrine] autoinjector) prescription
Guidelines for anaphylaxis emergency medication (adrenaline [epinephrine] autoinjector) prescription Introduction The aim of these guidelines is to outline the appropriate prescription of adrenaline (epinephrine)
More informationAllergy Action Plan For the 2015-2016 School Year
Allergy Action Plan Student s Name: DOB Grade ALLERGY TO: Asthmatic: Yes*[ ] No [ ] *Higher risk for severe reaction! STEP 1 TREATMENT Symptoms: Give checked medication To be determined by physician authorizing
More informationSeasonal Allergies. 1995-2012 The Patient Education Institute, Inc. www.x-plain.com im010101 Last reviewed: 05/30/2012 1
Seasonal Allergies Introduction Seasonal allergies are allergies that develop during certain times of the year. Seasonal allergies are usually a response to pollen from trees, grasses, and weeds. Constant
More informationDECODE them. Now you can do more than treat their allergies. You can
Now you can do more than treat their allergies. You can DECODE them. ImmunoCAP Specific IgE blood test gives you results on a panel of allergens tailored to your patients specific region to optimize your
More informationAllergy Emergency Treatment Protocol
Allergy Emergency Treatment Protocol I. Initial evaluation of possible allergic reaction a. Cease administration of allergenic extracts b. Notify physician c. Record vital signs: blood pressure, pulse,
More informationASTHMA IN INFANTS AND YOUNG CHILDREN
ASTHMA IN INFANTS AND YOUNG CHILDREN What is Asthma? Asthma is a chronic inflammatory disease of the airways. Symptoms of asthma are variable. That means that they can be mild to severe, intermittent to
More informationPERRYSBURG EXEMPTED VILLAGE SCHOOL DISTRICT
PERRYSBURG EXEMPTED VILLAGE SCHOOL DISTRICT MEDICATION IN SCHOOL 5330 F1/page 1 of 5 Before the student will be permitted to take medication during school hours or to use a self-administer medication and
More informationTest Request Tip Sheet
With/Without Contrast CT, MRI Studies should NOT be ordered simultaneously as dual studies (i.e., with and without contrast). Radiation exposure is doubled and both views are rarely necessary. The study
More informationFURTHER EXPERIENCE WITH SUBCUTANEOUS IMMUNOGLOBULIN THERAPY IN CHILDREN WITH PRIMARY IMMUNE DEFICIENCIES
FURTHER EXPERIENCE WITH SUBCUTANEOUS IMMUNOGLOBULIN THERAPY IN CHILDREN WITH PRIMARY IMMUNE DEFICIENCIES Dr Alison Jones Great Ormond Street Hospital for Children NHS Trust London WC1N 3JH United Kingdom
More informationEHR Demo Scenarios - Pediatrics. Female child 18 months old, here with mother for well child exam, including immunizations.
1. Well child scenario with complication Female child 18 months old, here with mother for well child exam, including immunizations. The patient s mother tells the front desk that there is a court order
More informationAllergy and Immunology Competency Based Goals and Objectives
Allergy and Immunology Competency Based Goals and Objectives COMPETENCY 1. Patient Care. Provide family centered patient care that is developmentally and age appropriate, compassionate, and effective for
More informationSelf Treatment for Seasonal Allergies. Veena Toledo, Pharm D LifeConnections Pharmacy
Self Treatment for Seasonal Allergies Veena Toledo, Pharm D LifeConnections Pharmacy Agenda Topics Oral Antihistamines and Decongestants Nasal Sprays Eye drops Non-drug Alternatives evidence / efficacy
More informationMILITARY (ACTIVE DUTY)-SPECIFIC ISSUES
RECOMMENDATIONS MILITARY (ACTIVE DUTY)-SPECIFIC ISSUES Evaluation for possible asthma 1. Active duty service members should be diagnosed with asthma or exerciseinduced bronchospasm on the basis of the
More informationManagement of food allergy in Europe - An overview using Germany as an example
Management of food allergy in Europe - An overview using Germany as an example Disclosure In relation to this presentation, I declare that there are no conflicts of interest. Allergy Societies in Europe
More informationFood Allergy Action Plan
Food Allergy Action Plan Name: D.O.B.: / / Allergy to: Weight: lbs. Asthma: Yes (higher risk for a severe reaction) No Place Student s Picture Here Extremely reactive to the following foods: THEREFORE:
More informationPosition Statement. Anaphylaxis in schools and other child-care settings August 1998 AAAAI Board of Directors
Position Statement Anaphylaxis in schools and other child-care settings August 1998 AAAAI Board of Directors AAAAI Position Statements and Work Group Reports are not to be considered to reflect current
More informationFerry Beach Ecology School Medical Management Plan -- Student with Chronic Illness or Severe Allergy
Medical Management Plan -- Student with Chronic Illness or Severe Allergy Students at Ferry Beach Ecology School (FBES) have full access to health services by a school nurse. The FBES nurse will identify
More informationTraining Manual & Speaker s Guide
Training Manual & Speaker s Guide Based on National Asthma Education and Prevention Program (NAEPP) Guidelines including the NAEPP s Guidelines Implementation Panel (GIP) Priority Messages. Funded in part
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Tysabri
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF I. Requirements for Prior Authorization of Tysabri A. Prescriptions That Require Prior Authorization All prescriptions for Tysabri must be prior authorized.
More informationPhysical Therapy MM.09.005 07/15/2003
Physical Therapy Policy Number: Original Effective Date: MM.09.005 07/15/2003 Line(s) of Business: Current Effective Date: HMO; PPO; EUTF; HSTA; QUEST; Federal Plan 87 09/28/2012 Line(s) of Business Excluded:
More informationIn the last few decades, asthma has become epidemic. As the most common
Licensed School Nurse/ Public Health Nurse/ Registered Nurse In the last few decades, asthma has become epidemic. As the most common chronic childhood disease, asthma affects more than six million children
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists
MEDICAL ASSISTANCE HBOOK `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists A. Prescriptions That Require Prior Authorization All prescriptions for Cytokine and CAM Antagonists must
More information4 Pharmacological management
4 Pharmacological management The aim of asthma management is control of the disease. Control of asthma is defined as: no daytime symptoms no night time awakening due to asthma no need for rescue medication
More informationAllergies and Autoimmune Inner Ear Disease
Allergies and Autoimmune Inner Ear Disease Allergy is the term used to describe an over-reaction of the body to a substance that is normally harmless to most people. This substance is called an allergen,
More informationMontelukast Sodium. -A new class of seasonal allergic rhinitis therapy
Montelukast Sodium -A new class of seasonal allergic rhinitis therapy Symptoms of Seasonal Allergic Rhinitis Nasal itch Sneezing Rhinorrhoea Nasal stuffiness Pathogenesis of Allergic Rhinitis Mast cells,
More informationLearn More About Product Labeling
Learn More About Product Labeling Product label The product label is developed during the formal process of review and approval by regulatory agencies of any medicine or medical product. There are specific
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: CSD - Suboxone Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Analgesics and Antipyretics (Opiate Partial Agonists) Client: County of San
More informationMedication Policy Manual. Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004
Medication Policy Manual Policy No: dru108 Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective
More informationRequired by statute (Chapter 423 of the Laws of 2014).
THE STATE EDUCATION DEPARTMENT / THE UNIVERSITY OF THE STATE OF NEW YORK / ALBANY, NY 12234 TO: FROM: SUBJECT: P-12 Education Committee Charles A. Szuberla, Jr. Proposed Addition of Section 136.7 of the
More informationJohn M. Kelso, MD, James T. Li, MD, PhD, and Matthew J. Greenhawt, MD, MBA
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 Update on Egg Allergy and Influenza Vaccine (Nov 2011) John M. Kelso, MD, James T. Li, MD,
More informationMESSA Saver Rx PRESCRIPTION DRUG RIDER BOOKLET. Good Health. Good Business. Great Schools.
MESSA Saver Rx PRESCRIPTION DRUG RIDER BOOKLET Good Health. Good Business. Great Schools. MESSA Saver Rx Prescription Drug Program The MESSA Saver Rx Prescription Drug Program is made available by a Group
More informationTreating Allergies, Hay Fever, and Hives
The Antihistamines: Treating Allergies, Hay Fever, and Hives Comparing Effectiveness, Safety, and Price Our Recommendations This report evaluates seven newer or second-generation antihistamine medications
More informationCetirizin "Copyfarm" 10 mg Filmcoated tablet Oral Energivej 15, POB 69 DK-5260 Odense S Denmark Netherlands. Cetirizine dihydrochloride
ANNEX I LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 CETIRIZINE DIHYDROCHLORIDE
More information